Therapeutic Context | Pathway | Effect | Association | Status | Evidence | Source |
---|---|---|---|---|---|---|
selumetinib | activation | gain-of-function | early trials | emerging | J Clin Oncol 2013;31: (suppl; abstr CRA9003) | |
PI3K pathway inhibitors + MEK inhibitors | activation | gain-of-function | preclinical | emerging | 22733540, 22808163 |
DoCM by The McDonnell Genome Institute at Washington University School of Medicine is licensed under a Creative Commons Attribution 4.0 International License. Questions? Comments? Concerns? You can contact us here.